【摘要】 弥漫性大B细胞淋巴瘤（DLBCL）继发中枢神经系统（CNS）侵犯是一种严重的临床并发症，发生率较低但预后通常很差。在高危因素鉴定方面需结合临床与分子生物学。治疗方案现包括以大剂量甲氨蝶呤（HD-MTX）为基础的化疗加利妥昔单抗（R）诱导治疗和强化化疗后自体造血干细胞移植（ASCT）或嵌合抗原受体T细胞免疫疗法（CAR-T），其中HD-MTX作用仍有争议，伊布替尼等酪氨酸激酶（BTK）抑制剂的治疗值得探讨。本文将讨论DLBCL继发CNS的高危因素、诊断及治疗。更多还原

【Abstract】 Secondary central nervous system(CNS) involvement in diffuse large B-cell lymphoma(DLBCL is a serious clinical complication, with a low incidence but usually poor prognosis. In the identification of high-risk factors, it is necessary to combine clinical and molecular biology. The treatment plan now includes the induction treatment of chemotherapy based on high-dose methotrexate(HD-MTX) with rituximab(R) and autologous stem cell transplantation(ASCT) or chimeric antigen receptor T-cell immunotherapy(CAR-T) after intensive chemotherapy. The role of HD-MTX is still controversial, and the treatment of Ibrutinib and other Bruton tyrosine kinase(BTK) inhibitors is worth exploring. In this review, the high-risk factors, diagnosis, and treatment of secondary CNS involvement in DLBCL will be discussed.更多还原